A macrolide widely used in severe SARS-CoV and MERS-CoV is being trialled by UK respiratory experts as a potential treatment for patients with moderately severe COVID-19. The multicentre phase II/III ATOMIC2 trial will compare azithromycin to standard care in adults presenting to hospital with COVID-19 symptoms who are not admitted at initial presentation. Led by Professor ...
Infectious diseases
Macrolide anti-inflammatory effects to be investigated in early COVID-19 diease
By Nicola Garrett
24 Aug 2020